Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,431 shares at $18.68 ($120K) on 2025-04-28, disclosed to the SEC on 2025-04-30.
Scheduled sale ($120k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.68 | 3,181 | $59K | 49.5% |
| 2 | $18.68 | 3,181 | $59K | 49.5% |
| 3 | $19.12 | 69 | $1K | 1.1% |
| Total | $18.68 avg | 6,431 | $120K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |